The Latest Cardiac and Vascular News
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) — Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted […]
REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) — Avinger(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first […]
REDWOOD CITY, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration (FDA) for […]
REDWOOD CITY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval for its next generation Pantheris Lumivascular atherectomy system, the first-ever […]
REDWOOD CITY, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, announced today […]
Beleaguered Avinger, Inc. is slashing more jobs. In its latest financial disclosure, Avinger reported a 61 percent decline in sales since the same time last year and would continue its strategic reorganization to save cash. The company said headcount has been reduced […]
REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) — Avinger(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2017 after the close of trading […]
REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of INSIGHT, a prospective, global, single arm, multi-center study to evaluate the safety and […]
REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the Pantheris® Lumivascular atherectomy system. […]
SAN DIEGO & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Avinger, Inc. (NasdaqGM: AVGR) on behalf of all purchasers of Avinger securities pursuant to the company’s initial public offering on […]
